Yeonjoo Hwang

Yeonjoo Hwang

Auto-generated profile, based on publicly available information

Yeonjoo Hwang

University of California, San Francisco

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
KLKevin Lou
Kevin Lou
VSVeronica Steri
Veronica Steri
AGAlex Y. Ge
Alex Y. Ge
YHY. Christina Hwang
Y. Christina Hwang
CYChristopher H. Yogodzinski
Christopher H. Yogodzinski
LGLuke A. Gilbert
Luke A. Gilbert
Inhibitors targeting KRASG12C, a mutant form of the guanosine triphosphatase (GTPase) KRAS, are a promising new class of oncogene-specific therapeutics for the treatment of tumors driven by the mutant protein. These inhibitors react with the mutant cysteine residue by binding covalently to the switch-II pocket (S-IIP) that is present only in the inactive guanosine diphosphate (GDP)–bound form of KRASG12C, sparing the wild-type protein. We used a genome-scale CRISPR interference (CRISPRi) functional genomics platform to systematically identify genetic interactions with a KRASG12C inhibitor in cellular models of KRASG12C mutant lung and pancreatic cancer. Our data revealed genes that were selectively essential in this oncogenic driver–limited cell state, meaning that their loss enhanced cellular susceptibility to direct KRASG12C inhibition. We termed such genes “collateral dependencies” (CDs) and identified two classes of combination therapies targeting these CDs that increased KRASG12C target engagement or blocked residual survival pathways in cells and in vivo. From our findings, we propose a framework for assessing genetic dependencies induced by oncogene inhibition.

11 June 2020 in Cancer Cell
Verified
Journal Article
Closed access
GCGarry L. Coles
Garry L. Coles
SCSandra Cristea
Sandra Cristea
JWJames T. Webber
James T. Webber
RLRebecca S. Levin
Rebecca S. Levin
SMSteven M. Moss
Steven M. Moss
JSJulien Sage
Julien Sage

9 February 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
ARAna Ruiz-Saenz
Ana Ruiz-Saenz
CAChloe E. Atreya
Chloe E. Atreya
CWChangjun Wang
Changjun Wang
BPBo Pan
Bo Pan
CDCourtney A. Dreyer
Courtney A. Dreyer
JCJean-Philippe Coppé
Jean-Philippe Coppé
BRAFV600E mutation confers a poor prognosis in metastatic colorectal cancer (CRC) despite combinatorial targeted therapies based on the latest understanding of signaling circuitry. To identify parallel resistance mechanisms induced by BRAF–MEK–EGFR co-targeting, we used a high-throughput kinase activity mapping platform. Here we show that SRC kinases are systematically activated in BRAFV600E CRC following targeted inhibition of BRAF ± EGFR and that coordinated targeting of SRC with BRAF ± EGFR increases treatment efficacy in vitro and in vivo. SRC drives resistance to BRAF ± EGFR targeted therapy independently of ERK signaling by inducing transcriptional reprogramming through β-catenin (CTNNB1). The EGFR-independent compensatory activation of SRC kinases is mediated by an autocrine prostaglandin E2 loop that can be blocked with cyclooxygenase-2 (COX2) inhibitors. Co-targeting of COX2 with BRAF + EGFR promotes durable suppression of tumor growth in patient-derived tumor xenograft models. COX2 inhibition represents a drug-repurposing strategy to overcome therapeutic resistance in BRAFV600E CRC.

15 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SCStephen Jun Fei Chong
Stephen Jun Fei Chong
FZFen Zhu
Fen Zhu
ODOlga Dashevsky
Olga Dashevsky
RMRin Mizuno
Rin Mizuno
JLJolin X.H. Lai
Jolin X.H. Lai
MDMatthew S. Davids
Matthew S. Davids
The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid malignancies such as diffuse large B cell lymphoma (DLBCL) are frequently intrinsically resistant to venetoclax. Although genomic resistance mechanisms such as BCL2 mutations have been described, this probably only explains a subset of resistant cases. Using 2 complementary functional precision medicine techniques — BH3 profiling and high-throughput kinase activity mapping — we found that hyperphosphorylation of BCL-2 family proteins, including antiapoptotic myeloid leukemia 1 (MCL-1) and BCL-2 and proapoptotic BCL-2 agonist of cell death (BAD) and BCL-2 associated X, apoptosis regulator (BAX), underlies functional mechanisms of both intrinsic and acquired resistance to venetoclax in CLL and DLBCL. Additionally, we provide evidence that antiapoptotic BCL-2 family protein phosphorylation altered the apoptotic protein interactome, thereby changing the profile of functional dependence on these prosurvival proteins. Targeting BCL-2 family protein phosphorylation with phosphatase-activating drugs rewired these dependencies, thus restoring sensitivity to venetoclax in a panel of venetoclax-resistant lymphoid cell lines, a resistant mouse model, and in paired patient samples before venetoclax treatment and at the time of progression.

24 January 2023 in eLife
Verified
Journal Article
Open access
GCGary Kl Chan
Gary Kl Chan
SMSamantha Maisel
Samantha Maisel
YHYeonjoo C Hwang
Yeonjoo C Hwang
BPBryan C Pascual
Bryan C Pascual
RWRebecca Rb Wolber
Rebecca Rb Wolber
JGJohn D Gordan
John D Gordan
Genetic alterations that activate protein kinase A (PKA) are found in many tumor types. Yet, their downstream oncogenic signaling mechanisms are poorly understood. We used global phosphoproteomics and kinase activity profiling to map conserved signaling outputs driven by a range of genetic changes that activate PKA in human cancer. Two signaling networks were identified downstream of PKA: RAS/MAPK components and an Aurora Kinase A (AURKA)/glycogen synthase kinase (GSK3) sub-network with activity toward MYC oncoproteins. Findings were validated in two PKA-dependent cancer models: a novel, patient-derived fibrolamellar carcinoma (FLC) line that expresses a DNAJ-PKAc fusion and a PKA-addicted melanoma model with a mutant type I PKA regulatory subunit. We identify PKA signals that can influence both de novo translation and stability of the proto-oncogene c-MYC. However, the primary mechanism of PKA effects on MYC in our cell models was translation and could be blocked with the eIF4A inhibitor zotatifin. This compound dramatically reduced c-MYC expression and inhibited FLC cell line growth in vitro. Thus, targeting PKA effects on translation is a potential treatment strategy for FLC and other PKA-driven cancers.

27 January 2022 in Oncogene
Verified
Journal Article
Open access
PDF file
JMJames E. Melnyk
James E. Melnyk
VSVeronica Steri
Veronica Steri
HNHao G. Nguyen
Hao G. Nguyen
YHY. Christina Hwang
Y. Christina Hwang
JGJohn D. Gordan
John D. Gordan
KSKevan M. Shokat
Kevan M. Shokat
The androgen receptor (AR) is a central driver of aggressive prostate cancer. After initial treatment with androgen receptor signaling inhibitors (ARSi), reactivation of AR signaling leads to resistance. Alternative splicing of AR mRNA yields the AR-V7 splice variant, which is currently an undruggable mechanism of ARSi resistance: AR-V7 lacks a ligand binding domain, where hormones and anti-androgen antagonists act, but still activates AR signaling. We reveal PKCβ as a druggable regulator of transcription and splicing at the AR genomic locus. We identify a clinical PKCβ inhibitor in combination with an FDA-approved anti-androgen as an approach for repressing AR genomic locus expression, including expression of AR-V7, while antagonizing full-length AR. PKCβ inhibition reduces total AR gene expression, thus reducing AR-V7 protein levels and sensitizing prostate cancer cells to current anti-androgen therapies. We demonstrate that this combination may be a viable therapeutic strategy for AR-V7-positive prostate cancer.